验证数据展示
经过测试的应用
| Positive FC detected in | human PBMCs |
推荐稀释比
| 应用 | 推荐稀释比 |
|---|---|
| This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
65503-1-RR targets HLA-DR in FC applications and shows reactivity with human samples.
| 经测试应用 | FC Application Description |
| 经测试反应性 | human |
| 免疫原 | Human lymphoblastoid B-cell line RPMI 8866 种属同源性预测 |
| 宿主/亚型 | Rabbit / IgG |
| 抗体类别 | Recombinant |
| 产品类型 | Antibody |
| 全称 | major histocompatibility complex, class II, DR alpha |
| 别名 | HLA-DRA, L243, HLA-DRA1, HLA DRB, HLA DRA1 |
| 计算分子量 | 254 aa, 29 kDa |
| GenBank蛋白编号 | BC032350 |
| 基因名称 | HLA-DRA |
| Gene ID (NCBI) | 3122 |
| ENSEMBL Gene ID | ENSG00000204287 |
| RRID | AB_3670291 |
| 偶联类型 | Unconjugated |
| 形式 | Liquid |
| 纯化方式 | Affinity purification |
| 储存缓冲液 | PBS with 0.09% sodium azide , pH 7.3 |
| 储存条件 | Store at 2-8°C. Stable for one year after shipment. |
背景介绍
HLA-DR is a member of MHC class II moleculesencoded by the human leukocyte antigen complex on the region 6p21.31 of chromosome 6. HLA-DR is composed of two non-covalently associated transmembrane glycoproteins (the α and β chains), and is primarily expressed on B lymphocytes, monocytes, dendritic cells and thymic epithelial cells (PMID: 33125816). HLA-DR participate in the antigen presentation to CD4+ or CD8+ T cells and is postulated as a general biomarker of sepsis-induced immunosuppression (PMID: 28199206, 32421903). The Anti-Human HLA-DR antibody, clone L243, is derived from Human lymphoblastoid B-cell line RPMI 8866.
实验方案
| Product Specific Protocols | |
|---|---|
| FC protocol for HLA-DR antibody 65503-1-RR | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
